Metabolon, Inc. has announced the acquisition of intellectual property from Cogenics Icoria, Inc., a subsidiary of Clinical Data, Inc.
The portfolio includes issued and pending patents related to metabolomics methods and data analysis as well as carcinogenicity and toxicity biomarkers. Metabolon now owns all of the metabolomics-related intellectual property formerly owned by Cogenics Icoria.
“The acquisition of this IP estate strengthens our IP position in this field,” said John Ryals, President and CEO of Metabolon. “The methods patents will enhance our leadership position as the world leader in metabolomics analysis. Furthermore, the biochemical biomarker patents will help drive our rapidly-developing diagnostics business.”